Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 25, 2021Journal of Clinical OncologyOpen Access

Phase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma

View Full Paper
Ask AI
Bookmark
Share

Authors

AMAlison J. MoskowitzMemorial Sloan Kettering Cancer CenterGSGunjan L. ShahMemorial Sloan Kettering Cancer CenterHSHeiko SchöderMemorial Sloan Kettering Cancer Center

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Moskowitz et al. (2021) studied this question.

synapsesocial.com/papers/69ffc679b124fe5819859cedhttps://doi.org/10.1200/jco.21.01056
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Early Interim 2-[ 18 F]Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography Is Prognostically Superior to International Prognostic Score in Advanced-Stage Hodgkin's Lymphoma: A Report From a Joint Italian-Danish Study2007 · 845 citations
  2. 2Pretransplant positive positron emission tomography/gallium scans predict poor outcome in patients with recurrent/refractory Hodgkin lymphoma2007 · 141 citations
  3. 3Brentuximab Vedotin Plus Bendamustine: A Highly Active Salvage Treatment Regimen for Patients with Relapsed or Refractory Hodgkin Lymphoma2015 · 62 citations
  4. 4IV. Masses in the mediastinum: primary mediastinal lymphoma and intermediate types2015 · 22 citations
  5. 5Results of a Trial of PET-Directed Therapy for Early-Stage Hodgkin’s Lymphoma2015 · 761 citations